Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1961. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Full Text available with Trip Pro

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Metformin is an oral anti-hyperglycemic agent used in the treatment of type 2 diabetes mellitus. The results of the UK Prospective Diabetes Study indicate that metformin treatment is associated with a reduction in total mortality compared to other anti-hyperglycemic treatments. Metformin, however, is thought to increase the risk of lactic acidosis, and is considered to be contraindicated in many chronic (...) hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age.To assess the incidence of fatal and nonfatal lactic acidosis with metformin use compared to placebo and other glucose-lowering treatments in patients with type 2 diabetes mellitus. A secondary objective was to evaluate the blood lactate levels for those on metformin treatment compared to placebo or non-metformin therapies.A search was performed

2002 Cochrane

1962. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). Full Text available with Trip Pro

Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). To estimate the incremental cost of implementing policies for intensive control of blood glucose concentration and blood pressure for all patients with type 2 diabetes in England.Extrapolation of resource use and cost data derived from a randomised controlled trial.General practice, outpatient care, and inpatient care.Trial population with diagnosed type 2 (...) diabetes in England extrapolated to the population of England.Total costs based on use of healthcare resources including costs of management, treatment, and hospitalisation.The incremental net annual cost of implementing intensive control of blood glucose and blood pressure to all people with diagnosed type 2 diabetes in England is estimated to be pound 100.5m ($156m; euro;159m), which is equivalent to less than 1% of the proposed additional annual expenditure on the NHS in 2001-5. This estimate varied

2002 BMJ Controlled trial quality: uncertain

1963. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. (Abstract)

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The worldwide increase in type 2 diabetes mellitus is becoming a major health concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of impaired glucose tolerance to type 2 diabetes.In a multicentre, placebo-controlled randomised trial, we randomly allocated patients with impaired glucose tolerance to 100 mg acarbose or placebo three times daily. The primary endpoint (...) or in addition to changes in lifestyle, to delay development of type 2 diabetes in patients with impaired glucose tolerance.

2002 Lancet Controlled trial quality: predicted high

1964. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Full Text available with Trip Pro

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. To evaluate whether a course teaching flexible intensive insulin treatment combining dietary freedom and insulin adjustment can improve both glycaemic control and quality of life in type 1 diabetes.Randomised design with participants either attending training immediately (immediate DAFNE) or acting as waiting list (...) controls and attending "delayed DAFNE" training 6 months later.Secondary care diabetes clinics in three English health districts.169 adults with type 1 diabetes and moderate or poor glycaemic control.Glycated haemoglobin (HbA(1c)), severe hypoglycaemia, impact of diabetes on quality of life (ADDQoL).At 6 months, HbA(1c) was significantly better in immediate DAFNE patients (mean 8.4%) than in delayed DAFNE patients (9.4%) (t=6.1, P<0.0001). The impact of diabetes on dietary freedom was significantly

2002 BMJ Controlled trial quality: uncertain

1965. Management of type II diabetes. Renal disease - prevention and early management - guideline

. Citation National Institute for Clinical Excellence. Management of type II diabetes. Renal disease - prevention and early management - guideline. London: National Institute for Clinical Excellence (NICE) 2002: 16 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order (...) to maximise the potential for reducing complications and improving the quality of life of people with the disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2 /complications; Diabetic Nephropathies /therapy /prevention & Guidelines as Topic; control Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800 Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk

2002 Health Technology Assessment (HTA) Database.

1966. Management of type II diabetes. Retinopathy - screening and early management - guideline

National Institute for Clinical Excellence. Management of type II diabetes. Retinopathy - screening and early management - guideline. London: National Institute for Clinical Excellence (NICE) 2002: 15 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order to maximise (...) the potential for reducing complications and improving the quality of life of people with the disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2 /complications; Diabetic Retinopathy /therapy; Guidelines as Topic; Vision Screening Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800 Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk AccessionNumber

2002 Health Technology Assessment (HTA) Database.

1967. Pancreatic islet transplantation for patients with type 1 diabetes mellitus

Pancreatic islet transplantation for patients with type 1 diabetes mellitus Pancreatic islet transplantation for patients with type 1 diabetes mellitus Pancreatic islet transplantation for patients with type 1 diabetes mellitus Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement (...) . Pancreatic islet transplantation for patients with type 1 diabetes mellitus. Bloomington MN: Institute for Clinical Systems Improvement (ICSI) 2002 Authors' objectives This review aims to assess the available evidence on the effectiveness of pancreatic islet transplantation for patients with type 1 diabetes mellitus. Authors' conclusions With respect to pancreatic islet transplantation for patients with type 1 diabetes mellitus, the ICSI Technology Assessment Committee finds: Pancreatic islet

2002 Health Technology Assessment (HTA) Database.

1968. Management of type II diabetes. Management of blood pressure and blood lipids

Excellence. Management of type II diabetes. Management of blood pressure and blood lipids. London: National Institute for Clinical Excellence (NICE) 2002: 44 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order to maximise the potential for reducing complications (...) and improving the quality of life of people with the disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Blood Pressure; Diabetes Mellitus, Type 2 /complications; Guidelines as Topic; Lipids /blood Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800 Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk AccessionNumber 32003000014 Date bibliographic record published 20/01/2003

2002 Health Technology Assessment (HTA) Database.

1969. Management of type II diabetes. Management of blood glucose

of blood glucose. London: National Institute for Clinical Excellence (NICE) 2002: 27 Authors' objectives This guideline is one of a series of five guidelines on type 2 diabetes. The aim of these guidelines is to provide guidance about managing type 2 diabetes for people with diabetes and the whole range of clinical staff who work in primary and secondary care, in order to maximise the potential for reducing complications and improving the quality of life of people with the disease. Project page URL (...) Indexing Status Subject indexing assigned by CRD MeSH Blood Glucose; Diabetes Mellitus, Type 2 /complications; Guidelines as Topic Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800 Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk AccessionNumber 32003000013 Date bibliographic record published 20/01/2003 Date abstract record published 20/01/2003 Health Technology Assessment (HTA) database

2002 Health Technology Assessment (HTA) Database.

1970. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus

Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Oduneye F Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Oduneye F. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 8 Authors' objectives This study aims to assess the effects of continuous insulin infusion pumps compared with multiple injection and conventional insulin therapy in people with type 1 diabetes mellitus. Authors' conclusions We found good evidence

2002 Health Technology Assessment (HTA) Database.

1971. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Full Text available with Trip Pro

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay (...) percent were members of minority groups.The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than

2002 NEJM Controlled trial quality: uncertain

1972. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Full Text available with Trip Pro

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. The purpose of this report is to summarize and integrate the findings of the Diabetes Control and Complications Trial (DCCT), a randomized controlled clinical trial, and the succeeding observational follow-up of the DCCT cohort in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, regarding the effects of intensive treatment on the microvascular complications of type 1 diabetes (...) of the DCCT remains less in the former intensive treatment group. Thus, the benefits of 6.5 years of intensive treatment extend well beyond the period of its most intensive implementation. Intensive treatment should be started as soon as is safely possible after the onset of type 1 diabetes mellitus and maintained thereafter, aiming for a practicable target HbA(1c) level of 7.0% or less.

2002 JAMA Controlled trial quality: uncertain

1973. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Full Text available with Trip Pro

Effects of insulin in relatives of patients with type 1 diabetes mellitus. It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes.In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had (...) at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups.In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.

2002 NEJM Controlled trial quality: uncertain

1974. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. Full Text available with Trip Pro

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. Type 1 diabetes mellitus is a chronic autoimmune disease caused by the pathogenic action of T lymphocytes on insulin-producing beta cells. Previous clinical studies have shown that continuous immune suppression temporarily slows the loss of insulin production. Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease.We studied (...) the effects of a nonactivating humanized monoclonal antibody against CD3--hOKT3gamma1(Ala-Ala)--on the loss of insulin production in patients with type 1 diabetes mellitus. Within 6 weeks after diagnosis, 24 patients were randomly assigned to receive either a single 14-day course of treatment with the monoclonal antibody or no antibody and were studied during the first year of disease.Treatment with the monoclonal antibody maintained or improved insulin production after one year in 9 of the 12 patients

2002 NEJM Controlled trial quality: uncertain

1975. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324: 705-708 PubMedID Original Paper URL Other publications of related interest 1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34. 2. Sutton AJ, Abrams KR, Jones DR, Sheldon T, Song F. Methods for meta (...) Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients

2002 DARE.

1976. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control

Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control Norris S L, Lau J, Smith S J, Schmid C H, Engelgau M M Authors' objectives To assess the effect on glycated haemoglobin (GHb) of diabetes self-management education (DSME (...) ) for adults with type 2 diabetes mellitus. Searching MEDLINE (from 1980 to December 1999), ERIC (from 1980 to 1999) and CINAHL (from 1982 to 1999) were searched for studies published in the English language; the search terms were stated. Abstracts and dissertations were not included. Journals of most relevance were handsearched and experts in the field were contacted for additional reports. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were

2002 DARE.

1977. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin (...) and postprandial glucose levels in a model of Type 2 diabetes mellitus Salas M, Ward A, Caro J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Combination therapy with nateglinide and metformin was compared with metformin monotherapy

2002 NHS Economic Evaluation Database.

1978. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of orlistat (Xenical) in obese Type 2 diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised obese Type 2 diabetic patients without micro- or macrovascular

2002 NHS Economic Evaluation Database.

1979. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes CDC Diabetes Cost-effectiveness Group Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three interventions aimed at reducing the occurrence of Type 2 diabetes were considered: intensive glycaemic control (insulin or sulfonylurea therapy), intensified hypertension control (angiotensin-converting enzyme

2002 NHS Economic Evaluation Database.

1980. Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial

Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 NHS Economic Evaluation Database.